טוען...
Phase I/II Trial of 5-Fluorouracil and a Noncytotoxic Dose Level of Suramin in Patients with Metastatic Renal Cell Carcinoma
BACKGROUND: Renal cell carcinoma (RCC) is recognized as a neoplasm resistant to chemotherapy. In vitro experiments demonstrated that suramin, at noncytotoxic doses, enhanced the activity of chemotherapy including 5-fluorouracil (5-FU) in xenograft models. PATIENTS AND METHODS: A phase I/II trial of...
שמור ב:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2008
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2877588/ https://ncbi.nlm.nih.gov/pubmed/18824429 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3816/CGC.2008.n.012 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|